Gadolinium and systemic fibrosis: guilt by association.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

4 citing papers in PubMed.

1. Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation.Annals of the rheumatic diseases · 2015
   Article
2. Role of modern imaging techniques in hand osteoarthritis research and clinical practice.Current rheumatology reports · 2014
   Review
3. Manganese-based MRI contrast agents: past, present and future.Tetrahedron · 2011
   Article
4. Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.Nature reviews. Endocrinology · 2011
   Review

Corrections and comments

• Comment on
  Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis.2010
• Comment on
  NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis.2010

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as